Hypersensitivity Reactions to the GLP-1 Receptor Agonists Liraglutide and Semaglutide: A Case Series
J Investig Allergol Clin Immunol. 2024 Apr;34(2):133-135. doi: 10.18176/jiaci.0932.NO ABSTRACTPMID:38639450 | DOI:10.18176/jiaci.0932 (Source: Journal of Investigational Allergology and Clinical Immunology)
Source: Journal of Investigational Allergology and Clinical Immunology - April 19, 2024 Category: Allergy & Immunology Authors: B Barroso A G ómez-López M Valverde-Monge D Betancor M de Las Heras J Sastre Source Type: research
Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
ConclusionThe present GL is directed to all physicians addressing people with obesity —working in hospitals, territorial services or private practice—and to general practitioners and patients. The recommendations should also consider the patient’s preferences and the available resources and expertise. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - April 17, 2024 Category: Endocrinology Source Type: research
Therapy combining glucagon-like peptide-1 receptor agonist with sodium-glucose cotransporter 2 inhibitor suppresses atherosclerosis in diabetic ApoE-deficient mice
Conclusions Our data suggest that combination therapy with liraglutide and ipragliflozin may be an efficient regimen for preventing the development of atherosclerosis in diabetic ApoE-deficient mice.PMID:38626913 | DOI:10.1055/a-2307-8036 (Source: Atherosclerosis)
Source: Atherosclerosis - April 16, 2024 Category: Cardiology Authors: Masahiro Takubo Kentaro Watanabe Hitoki Saito Genta Kohno Hisamitsu Ishihara Source Type: research
Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study
ConclusionsOur study emphasizes the important role of IDegLira in maintaining a good metabolic control while minimizing the risk of major hypoglycemia and weight gain in the long term. The substantial simplification of treatment schemes can increase adherence. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 11, 2024 Category: Endocrinology Source Type: research
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
In this study, we explored the anti-HFpEF effects of empagliflozin and liraglutide and the underlying molecular mechanisms in a mouse model of HFpEF. This model was established by high-fat diet (HFD) feeding plus Nω-nitro-L-arginine methyl ester (L-NAME) treatment. The mice were treated with empagliflozin (20 mg·kg-1·d-1, i.g.) or liraglutide (0.3 mg·kg-1·d-1, i.p.) or their combination for 4 weeks. At the end of the experimental protocol, cardiac function was measured using ultrasound, then mice were euthanized and heart, liver, and kidney tissues were collected. Nuclei were isolated from frozen mouse ventricular tis...
Source: Acta Pharmacologica Sinica - April 8, 2024 Category: Drugs & Pharmacology Authors: Xia-Yun Ni Xiao-Jun Feng Zhi-Hua Wang Yang Zhang Peter J Little Yang Cao Suo-Wen Xu Li-Qin Tang Jian-Ping Weng Source Type: research
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
In this study, we explored the anti-HFpEF effects of empagliflozin and liraglutide and the underlying molecular mechanisms in a mouse model of HFpEF. This model was established by high-fat diet (HFD) feeding plus Nω-nitro-L-arginine methyl ester (L-NAME) treatment. The mice were treated with empagliflozin (20 mg·kg-1·d-1, i.g.) or liraglutide (0.3 mg·kg-1·d-1, i.p.) or their combination for 4 weeks. At the end of the experimental protocol, cardiac function was measured using ultrasound, then mice were euthanized and heart, liver, and kidney tissues were collected. Nuclei were isolated from frozen mouse ventricular tis...
Source: Acta Pharmacologica Sinica - April 8, 2024 Category: Drugs & Pharmacology Authors: Xia-Yun Ni Xiao-Jun Feng Zhi-Hua Wang Yang Zhang Peter J Little Yang Cao Suo-Wen Xu Li-Qin Tang Jian-Ping Weng Source Type: research
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
In this study, we explored the anti-HFpEF effects of empagliflozin and liraglutide and the underlying molecular mechanisms in a mouse model of HFpEF. This model was established by high-fat diet (HFD) feeding plus Nω-nitro-L-arginine methyl ester (L-NAME) treatment. The mice were treated with empagliflozin (20 mg·kg-1·d-1, i.g.) or liraglutide (0.3 mg·kg-1·d-1, i.p.) or their combination for 4 weeks. At the end of the experimental protocol, cardiac function was measured using ultrasound, then mice were euthanized and heart, liver, and kidney tissues were collected. Nuclei were isolated from frozen mouse ventricular tis...
Source: Acta Pharmacologica Sinica - April 8, 2024 Category: Drugs & Pharmacology Authors: Xia-Yun Ni Xiao-Jun Feng Zhi-Hua Wang Yang Zhang Peter J Little Yang Cao Suo-Wen Xu Li-Qin Tang Jian-Ping Weng Source Type: research
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
Acta Pharmacologica Sinica, Published online: 08 April 2024; doi:10.1038/s41401-024-01265-0Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - April 8, 2024 Category: Drugs & Pharmacology Authors: Xia-yun Ni Xiao-jun Feng Zhi-hua Wang Yang Zhang Peter J. Little Yang Cao Suo-wen Xu Li-qin Tang Jian-ping Weng Source Type: research
Correction to: Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK ‑3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high‑fat dietstreptozocin rat model
Pflugers Arch. 2024 Apr 5. doi: 10.1007/s00424-024-02959-4. Online ahead of print.NO ABSTRACTPMID:38575720 | DOI:10.1007/s00424-024-02959-4 (Source: Pflugers Archiv : European Journal of Physiology)
Source: Pflugers Archiv : European Journal of Physiology - April 4, 2024 Category: Physiology Authors: Hoda M Moghazy Nesreen G Abdelhaliem Sherine Ahmed Mohammed Asmaa Hassan Amany Abdelrahman Source Type: research
Correction to: Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK ‑3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high‑fat dietstreptozocin rat model
Pflugers Arch. 2024 Apr 5. doi: 10.1007/s00424-024-02959-4. Online ahead of print.NO ABSTRACTPMID:38575720 | DOI:10.1007/s00424-024-02959-4 (Source: Pflugers Archiv : European Journal of Physiology)
Source: Pflugers Archiv : European Journal of Physiology - April 4, 2024 Category: Physiology Authors: Hoda M Moghazy Nesreen G Abdelhaliem Sherine Ahmed Mohammed Asmaa Hassan Amany Abdelrahman Source Type: research
Sex, Racial, Ethnic, and Geographical Disparities in Major Adverse Cardiovascular Outcome of Glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A Meta-analysis of Placebo-Controlled Randomized Controlled Trials
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a first-line drug in treating type 2 diabetes mellitus (T2DM).1 GLP-1RAs have also been found to significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM, as demonstrated by multiple large cardiovascular outcome trials (CVOTs).2, 3 The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial (2016), which aimed to determine the cardiovascular (CV) effects of liraglutide marked a turning point and was the first to show a reduction in major adverse cardiovascular events (...
Source: Journal of Clinical Lipidology - April 4, 2024 Category: Lipidology Authors: Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw Tags: Original Research Source Type: research
Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery
AbstractPreoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-m ass index ≥ 48 kg/m2. All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the...
Source: Updates in Surgery - April 4, 2024 Category: Surgery Source Type: research
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
CONCLUSION: Our findings suggest a potential consideration for repurposing anti-diabetic weight loss-inducing drugs including semaglutide, dulaglutide, and liraglutide (glucagon-like peptide-1 receptor agonists), empagliflozin (sodium-glucose cotransporter-2 inhibitor), and metformin (biguanide), for MS. This warrants validation through rigorous methodologies and prospective studies.PMID:38566910 | PMC:PMC10986166 | DOI:10.1177/17562864241241383 (Source: Adv Data)
Source: Adv Data - April 3, 2024 Category: Epidemiology Authors: Afsaneh Shirani Anne H Cross Olaf Stuve Source Type: research
Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation
Eur J Pharmacol. 2024 Mar 30:176525. doi: 10.1016/j.ejphar.2024.176525. Online ahead of print.ABSTRACTDepression is a debilitating mental disease that negatively impacts individuals' lives and society. Novel hypotheses have been recently proposed to improve our understanding of depression pathogenesis. Impaired neuroplasticity and upregulated neuro-inflammation add-on to the disturbance in monoamine neurotransmitters and therefore require novel anti-depressants to target them simultaneously. Recent reports demonstrate the antidepressant effect of the anti-diabetic drug liraglutide. Similarly, the natural flavonoid naringen...
Source: European Journal of Pharmacology - April 1, 2024 Category: Drugs & Pharmacology Authors: Yara S Abdelkawy Mona Elharoun Eman Sheta Ihab Talat Abdel-Raheem Hisham A Nematalla Source Type: research
